Schizophrenia International Research Society
APRIL 3-7, 2024
FLORENCE, ITALY
CLINICAL POSTERS
The scientific posters accessible via this website have been developed and financially supported by Sumitomo Pharma America, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc.
Copies of posters obtained through this site are for personal use only and may not be reproduced without written permission from the authors.
A RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ULOTARONT IN PATIENTS WITH SCHIZOPHRENIA
Leslie Citrome, Heather Dworak, Kenneth S. Koblan, Robert Goldman, Hailong Cheng, Alison Fitzgerald, Antony Loebel, Armin Szegedi
Download the PDF: CLICK HERE
EFFECT OF ULOTARONT ON BRAIN DOPAMINESYNTHESIS CAPACITY IN SUBJECTS WITH SCHIZOPHRENIA ON STABLE DOSES OF A D2 ANTIPSYCHOTIC: RESULTS OF AN 18F-DOPA PET STUDY
Oliver D. Howes, Luke Vano, Grazia Rutigliano, Robert McCutcheon, Robert Lew, Snezana Milanovic, Lisa Lennek, Seth C. Hopkins, Kenneth S. Koblan
Download the PDF: CLICK HERE
ULOTARONT IN THE TREATMENT OF SCHIZOPHRENIA: POST-HOC ANALYSES OF TWO 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIALS
Heather Dworak, Nicholas DeMartinis, Robert Goldman, Yan Li, Kenneth S. Koblan, Armin Szegedi
Download the PDF: CLICK HERE
ULOTARONT DELAYS GASTRIC EMPTYING OF SOLIDS IN SCHIZOPHRENIA PATIENTS WITH METABOLIC SYNDROME AND PREDIABETES
Snežana Milanović, Nina Dedic, Robert Lew, Kenneth S. Koblan, Michael Camilleri, Seth C. Hopkins
Download the PDF: CLICK HERE
TAAR1 AGONIST ULOTARONT MODULATES STRIATAL AND HIPPOCAMPAL GLUTAMATE FUNCTION IN A STATE-DEPENDENT MANNER
Sung M. Yang, Ayan Ghoshal, Jeffrey Hubbard, Florian Gackière, Romain Teyssié, Stuart A. Neale, Seth C. Hopkins, Kenneth S. Koblan, Linda J. Bristow and Nina Dedic
Download the PDF: CLICK HERE